35 results about "Truncated protein" patented technology

The application belongs to the technical field of bioengineering, and particularly relates to application of a riboflavin kinase / FMN adenosine transferase truncated protein and a mutant thereof in FMN synthesis. The application obtains a mutant with improved riboflavin kinase enzyme activity by truncating and mutating RibFM-1, and uses the mutant in FMN production. The FMN yield of the strain containing the truncated protein gene is increased by 49.14%, 33.97%, 43.58%, 22.42%, 76.31% and 113.70% respectively compared with the strain containing the non-truncated gene. It can be seen that the riboflavin kinase / FMN adenosine transferase can significantly improve the yield of FMN after being truncated or mutated, and has a wide application potential in FMN industrial production.

This patent application discloses a recombinant human type II collagen, its preparation method, and its uses. The recombinant human type II collagen of this patent application is a truncated protein of natural human type II collagen, and its amino acid sequence is shown in SEQ ID No: 1. The recombinant human type II collagen of this invention can be expressed in commercial expression systems such as the commercial Pichia pastoris expression system with high expression yields. Furthermore, its tested biological activities (promoting cell proliferation and wound healing) are significantly superior to those of natural human type II collagen, and also significantly superior to other stages of natural human type II collagen.

The application discloses a colloidal gold test strip for distinguishing between wild toxin infection and vaccine immunization of porcine pleuropneumonia actinobacillus and application. The test strip of the application takes ApxIVA truncated protein with an amino acid sequence shown as SEQ ID NO. 3 as an antigen, the truncated protein can be soluble expressed in E. coli, and the structure and function of the truncated protein are close to those of natural apxIVA. The test strip of the application comprises a sample pad, a colloidal gold pad, an NC membrane, a water absorption filter paper and a bottom plate, the colloidal gold pad is coated with gold-labeled apxIVA truncated protein and gold-labeled chicken IgY antibody, and the C line and the T line of the NC membrane are fixed with goat anti-chicken IgY antibody and apxIVA truncated protein. The test strip only needs 25 muL of pig serum to make detection within 5-10 min, and can distinguish between APP wild strain infection and gene deletion vaccine APP-HB-04M immunized serum samples.

The invention provides an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) Nsp4 protein monoclonal antibody with an inhibition effect and application thereof, a hybridoma cell strain capable of stably secreting the anti-Nsp4 protein monoclonal antibody is prepared, and a new antigen epitope is identified in nsp4 through expressed overlapping truncated protein. Wherein the 123ITEAGELV130 identified by the monoclonal antibody 1C11 shows the potential of universally identifying different types of PRRSV (Porcine Reproductive and Respiratory Syndrome Virus). Meanwhile, expression of Nsp4 protein can be detected in the early stage of PRRSV infection by utilizing the monoclonal antibody 1C11, the monoclonal antibody has a blocking effect on PRRSV positive serum, and it is found that the monoclonal antibody 1C11 can inhibit proliferation of PRRSV in vitro. Research results increase the understanding of PRRSV Nsp4 protein structure and antigen characteristics, and provide a basis for PRRSV early antigen detection.

To provide adeno-associated variants, formulations and methods for pulmonary delivery.SOLUTION: The present disclosure provides variant AAV capsid proteins that confer tropism for lung cells, as well as recombinant adeno-associated viruses comprising the variant AAVs and pharmaceutical compositions comprising the same, and their use in the delivery of heterologous nucleic acids to lung cells for the treatment of lung disorders. (ii) nucleic acids comprising, from 5 ' to 3 ', (a) AAV2 terminal repeats, (b) a promoter, (c) a nucleotide sequence encoding a human cystic fibrosis transmembrane conductance regulator (CFTR) or a biologically active truncated CFTR lacking amino acids 708 to 759 of the human CFTR sequence, (d) a poly-adenylation sequence, and (e) AAV2 terminal repeats.SELECTED DRAWING: None

The invention relates to the technical field of biology, in particular to engineered nuclease and application thereof, and particularly, nuclease with small protein molecular weight is obtained by optimizing a Cas protein structural domain. Through modification and optimization of a Cas protein structural domain, it is found that the truncated protein composed of PI, REC-I and WED structural domains at the N end of the V-type Cas protein can give play to the activity of nuclease, and a new path and a new research direction are provided for development and application of nuclease.

Methods and devices to capture and analyze aerosolized particles such as protein biomarkers and their truncated proteoforms characteristic of a disease, including a respiratory disease, in exhaled breath to enable rapid detection of diseases are disclosed. The disclosed methods and systems selectively capture aerosolized particles using a packed bed column. The captured particles are then eluted using one or more solvents and analyzed using devices including mass spectrometry.

The invention provides an IGF2BP3 truncated protein mutant, an overexpression vector and application of the IGF2BP3 truncated protein mutant and belongs to the technical field of genetic engineering, and the IGF2BP3 truncated protein mutant is any one of the following items: 1) a truncated protein mutant I obtained by truncating a KH1-4 structural domain on the basis of IGF2BP3 wild type protein; 2) a truncated protein mutant II obtained by truncating a KH1-2 structural domain on the basis of IGF2BP3 wild type protein; 3) a truncated protein mutant III obtained by truncating a KH3-4 structural domain on the basis of IGF2BP3 wild-type protein.According to the invention, the specific KH structural domain can be systematically disassembled and studied through the obtained different IGF2BP3 truncated protein mutants, and further understanding of the functional mechanism of IGF2BP3 is promoted.

The invention provides a PMFBP1 mutant gene related to azoospermia syndrome and an application of the PMFBP1 mutant gene. The mutant gene is a PMFBP1 gene c.2641Cgt; the protein p.Arg881Ter is subjected to non-sense mutation, so that the encoded protein p.Arg881Ter is truncated, and the function of a sperm head-tail connection device is damaged. The invention also provides a specific Sanger sequencing detection method and a kit of the mutation, which can be used for rapid molecular diagnosis, genetic counseling and assisted reproduction guidance of the disease, and provides a basis for precise medical treatment.

The invention discloses an IgG and IgA antibody detection kit based on porcine rotavirus VP8 protein as well as a preparation method and application of the IgG and IgA antibody detection kit. The kit comprises an elisa plate, positive control serum, negative control serum, an elisa secondary antibody, a sample diluent, a 20-time concentrated washing solution, a substrate solution A, a substrate solution B and a stop solution, wherein the elisa plate is coated with VP8 truncated protein of a porcine rotavirus epidemic strain expressed by mammalian cells. According to the kit, the IgG antibody and the IgA antibody of the porcine rotavirus can be detected at the same time under the condition that only one reagent (enzyme-labeled antibody) is added, and evaluation on the titer of the whole antibody is facilitated. The kit disclosed by the invention is high in sensitivity, high in specificity, good in stability, convenient to operate and relatively high in universality, and has a good market prospect.

The invention discloses a porcine TMEM106a protein polyclonal antibody as well as a preparation method and application thereof, and belongs to the technical field of biology. The pig TMEM106a protein polyclonal antibody is prepared by taking a protein with a sequence as shown in SEQ ID NO.2 as an antigen and carrying out animal immunization. According to the invention, a pig TMEM106a truncated protein segment is utilized to prepare the pig TMEM106a protein polyclonal antibody. The pig TMEM106a protein polyclonal antibody prepared by the invention is strong in specificity and high in titer, and can specifically recognize the TMEM106a protein in pig source cells, so that the pig TMEM106a protein polyclonal antibody can be applied to a pig TMEM106a protein detection reagent or kit. Important tools and technical supports are provided for functional research of the TMEM106a protein on pigs, and the method is suitable for large-scale popularization, production and application.

The invention provides a subunit vaccine composition of a bovine nodular skin disease virus as well as a preparation method and application of the subunit vaccine composition. The subunit vaccine composition comprises subunit ORF61 protein and subunit ORF142 protein of the bovine nodular skin disease virus and a pharmaceutically acceptable adjuvant, the subunit ORF61 protein is an extracellular truncated protein of the ORF61 protein, and the amino acid sequence of the subunit ORF61 protein is as shown in SEQ ID NO. 1; the subunit ORF142 protein is an extracellular truncated protein of the ORF142 protein, and the amino acid sequence of the subunit ORF142 protein is as shown in SEQ ID NO. 2. The subunit vaccine composition for the bovine nodular skin disease virus has excellent immunogenicity and stability of ORF61 protein and ORF142 protein of the bovine nodular skin disease virus, is convenient for stable and efficient secretory expression in engineered cell strains, is high in yield and easy to purify, and has the characteristics of efficient secretory expression, high protein purity, reduced production cost, high safety and the like.

The application provides mRNA based on HEV ORF2 truncated protein, a preparation method and application thereof, the mRNA based on HEV ORF2 truncated protein includes 5'UTR region, SP fragment, 3'UTR region, 3' terminal poly A tail, gene for encoding hepatitis E virus ORF2 truncated protein and 5' cap structure, the hepatitis E virus ORF2 truncated protein is ORF2-239aa protein or ORF2-549aa protein, the nucleotide sequence of the gene for encoding the ORF2-239aa protein is shown as SEQ ID NO.1, the nucleotide sequence of the gene for encoding the ORF2-549aa protein is shown as SEQ ID NO.2, the application has application value in hepatitis E research and vaccine creation, and can greatly promote the transformation application of vaccine.

The present application relates to a truncated IgA protease, a fusion protein comprising the truncated IgA protease (e.g., a fusion protein comprising the truncated IgA protease and an Fc), and use thereof in treating an IgA deposition disease (e.g., IgA nephropathy).

The invention provides an expression cassette, a recombinant expression vector, a genetically engineered bacterium, a construction method, a culture method and an application, and particularly belongs to the technical field of genetic engineering. The invention provides an expression cassette. The expression cassette comprises a SpaC truncated protein gene, an antioxidant enzyme three-enzyme coupling system fusion protein gene and a cytokine fusion protein gene, the expression cassette further comprises a surface display system for presenting the SpaC truncated protein on the surface of the cell; the antioxidant enzyme three-enzyme coupling system fusion protein is fused with catalase, superoxide dismutase and glutathione peroxidase. The cytokine fusion protein is fused with a YebF protein and a trefoil factor 3 protein. The expression cassette provided by the invention has the function of improving the adhesion colonization ability of the EcN strain, can improve the active oxygen scavenging ability of the EcN strain and repair the intestinal epithelial barrier function, is high in safety, and can realize more effective treatment of inflammatory bowel diseases.

The invention relates to the technical field of disease diagnosis, and provides a specific biomarker for granulomatous mastitis and a preparation method and application thereof, the specific biomarker is nicotinamide phosphoribosyltransferase truncated protein, and the amino acid sequence of the specific biomarker is shown as SEQ ID NO. 1. The NAMPT truncated protein is a specific molecule directly related to the GM pathogenesis. The detection result has high directivity, the positive result supports GM diagnosis, and the negative result is helpful for eliminating the GM diagnosis, so that non-iconography objective evidence is provided for differential diagnosis. GM and breast cancer are clearly distinguished in the early stage of diagnosis, and unnecessary anti-cancer treatment or delay of the real illness state is avoided.

This invention discloses a recombinant lactic acid bacteria expressing a truncated avian adenovirus Hexon protein, its construction method, and its applications, belonging to the field of biomedical technology. This invention is the first to construct recombinant lactic acid bacteria strains pNZ8149-FAdV4ΔHexon / NZ3900 and pNZ8149-FAdV8bΔHexon / NZ3900 expressing the truncated avian adenovirus Hexon protein. SDS-PAGE and Western blotting analyses showed that the exogenous genes FADV4-ΔHexon and FADV-8bΔHexon were successfully expressed in *Lactococcus lactis* and exhibited reactivity. Oral immunization of one-day-old chicks showed that oral administration of the recombinant lactic acid bacteria induced humoral and cellular immunity, as well as local mucosal immunity. The results indicate that the recombinant constitutive lactic acid bacteria prepared in this invention can enhance the immunity of chicks.

The present invention relates to a cell which comprises a chimeric antigen receptor (CAR) and a signal transduction modifying protein, selected from one of the following: (i) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM), but lacks a kinase domain; (ii) a truncated protein which comprises an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a phosphatase domain; (iii) a fusion protein which comprises (a) an SH2 domain from a protein which binds a phosphorylated immunoreceptor tyrosine-based activation motif (ITAM) or from a protein which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM); and (ii) a heterologous domain.

Provided are an epitope or epitope peptide of a respiratory syncytial virus (RSV) F protein, and a fusion protein containing the epitope or epitope peptide and a truncated F protein of human metapneumovirus (hMPV) or a variant of the truncated protein. Further provided are the use of the fusion protein and of a vaccine, an immunogenic composition, a kit, and a pharmaceutical composition containing same in preventing and / or treating RSV and / or hMPV infection or diseases and / or symptoms caused by RSV and / or hMPV infection.

Methods to purposefully target lytic granules to the cell membrane following NK cell activation for the benefit of bystander killing in a solid tumor setting as novel cell therapy approach. These methods can be used alone or in combination with dispersion related strategies. Methods of using truncated proteins from the dynein-dynactin complex to block dynein function to induce lytic granule dispersion. The methods and compositions enhance the lethality of degranulation events. The methods and compositions can boost cytotoxicity in a solid tumor directly or be combined with other technologies, such as immunotherapies to improve their outcomes.

Small peptides, and a use thereof in the preparation of a medicament for treating cancer. Provided are a group of DSP small peptides, as well as full-length and truncated DDR1 proteins, all of which have the same active structure. Using in vivo tumor experiments, it is demonstrated that this group of DSP small peptides or truncated proteins can increase stem-like CD8+ memory T cells in bone marrow, and enhance the cytotoxic activity of CD8+ effector T cells, ultimately inhibiting the metastasis of lung cancer cells to brain tissue. In vitro, it is demonstrated that they have cytotoxic effects on tumor cells of eight types, including lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, liver cancer, pancreatic cancer and bladder cancer.

The invention discloses application of a PTCHD1 gene mutant and a detection reagent. Belongs to the technical field of gene mutation detection. According to the mutation, compared with a wild type PTCHD1 gene, cytosine C is replaced with adenine A at the 1644th nucleotide of a coding sequence, so that protein translation is terminated in advance at the 548th amino acid, and a truncated protein is formed. And the c.1644Cgt of the PTCHD1 gene is confirmed; a is pathogenic nonsense mutation causing AUTS4, a new insight is provided for the genetic basis of the disease, and the blank of the mutation spectrum of the disease is filled.

Methods and devices to capture and analyze aerosolized particles in exhaled air including protein biomarkers and their truncated proteoforms characteristic of tuberculosis to enable rapid detection of diseases. Methods and systems to selectively capture aerosolized particles using a packed bed column. The captured particles are eluted using one or more solvents and analyzed using devices including MALDI-TOFMS.

The invention discloses a recombinant human IV type collagen as well as a production method and application thereof. The amino acid sequence of the recombinant human IV type collagen is shown as SEQ ID No: 1. The recombinant human IV-type collagen is a truncated protein of a human IV-type collagen alpha2 chain, special expression elements and means are not needed, the yield of the recombinant human IV-type collagen can reach up to 17g / L only through extracellular secretion expression of a commercial pichia pastoris expression system, the yield is obviously higher than the high yield level of recombinant collagen considered in the technical field, and the recombinant human IV-type collagen has a good application prospect. And the total length of the alpha 2 chain of the human IV-type collagen or other truncated proteins is obviously higher than that of the human IV-type collagen. In addition, the safety and biological activity of the recombinant human IV-type collagen are superior to the full length of the alpha 2 chain of the human IV-type collagen.

The application discloses a specific goatpox virus P32 truncated protein and application thereof in vaccine efficacy detection. The amino acid sequence of the protein is shown as SEQ ID NO: 3. The specific truncated form (aa1-aa238) has significantly better soluble expression in E. coli than the full-length and other truncated forms (such as aa1-aa277). A competitive ELISA method for quantitatively detecting the efficacy of bovine nodular skin disease inactivated vaccine is established by taking the specific truncated form as a coating antigen. The method is systematically optimized, and has high sensitivity, strong specificity and good repeatability. Key is that the relative efficacy (RP) value measured by the method is highly correlated with animal challenge protection results, and when the RP value is greater than or equal to 1.0, complete immune protection can be predicted, so that the traditional animal challenge test can be reliably replaced. Compared with the immune challenge method, the detection period is greatly shortened (from 63 days to 2 days), target animals are not used, the detection cost is saved, and the method does not need P3 laboratory conditions and has no biosafety risk.

The application discloses an indirect ELISA kit for distinguishing between wild-type Actinobacillus pleuropneumoniae (APP) infection and vaccine immunization and application thereof, and belongs to the technical field of biology.The indirect ELISA kit is characterized in that a screened ApxIVA truncated protein is used as a coating antigen, the amino acid sequence of the ApxIVA truncated protein is shown as SEQ ID NO.3, the ApxIVA truncated protein can be expressed in a soluble manner in Escherichia coli, only carries one His tag and S tag, and is close to natural ApxIVA in structure and function.The indirect ELISA kit is characterized in that the ApxIVA truncated protein is used as an antigen, an indirect ELISA method and kit for distinguishing between wild-type APP infection and gene deletion vaccine immunization are established, the kit has the advantages of high specificity, low background value, low cost and short detection time, and has important significance in improving the diagnostic accuracy of livestock and poultry APP, optimizing prevention and control measures, guaranteeing animal health and production efficiency.

The invention relates to the technical field of veterinary biological products, and particularly provides feline herpesvirus type I antigen protein, a subunit vaccine and application of the feline herpesvirus type I antigen protein and the subunit vaccine. The 68th-771st amino acids from the N terminal of gB are selected as gB truncated protein, the 1st-504th amino acids from the N terminal of gC are selected as gC truncated protein, the 1st-328th amino acids from the N terminal of gD are selected as gD truncated protein, and further, the C terminals of the gB truncated protein, the gC truncated protein and the gD truncated protein are independently connected with mouse IgG2a Fc receptor binding domain sequences (CH2-CH3) through flexible Linker, so that the recombinant expression protein is obtained. The antigen protein is used as an effective component for preparing a subunit vaccine, an antibody for preventing viruses from invading host cells can be induced to generate, the uptake efficiency of antigen presenting cells is remarkably improved, the immune response of a body is enhanced, and cells infected by the viruses are killed and removed.

The invention discloses a recombinant fusion protein subunit vaccine of an infectious spleen and kidney necrosis virus as well as a preparation method and application of the recombinant fusion protein subunit vaccine. The truncated protein of the main capsid protein of the infectious spleen and kidney necrosis virus and the truncated protein of the 051L protein form the recombinant fusion protein t051L-tMCP, and the recombinant fusion protein can simultaneously express dominant epitopes of two immunizing antigens and can be stirred and mixed with an oil-in-water emulsion adjuvant to prepare a vaccine preparation. Experiments prove that the recombinant fusion protein subunit vaccine has high immunogenicity and can recognize and combine tMCP and t051L, and the relative immune protection rate of a 1.0 mg / mL dosage group reaches 95.50%. The recombinant fusion protein provided by the invention is simple to prepare and operate, and the prepared vaccine not only solves the bottleneck problem of low immunogenicity of an infectious spleen and kidney necrosis virus subunit vaccine, but also can be widely applied to protection of fry against infectious spleen and kidney necrosis virus infection in the breeding process of micropterus salmoides.

Designed coronavirus polypeptide sequences are described, and their use as vaccines against viruses of the coronavirus family. The designed sequences include designed coronavirus spike(S) proteins and fragments thereof, including designed S protein receptor binding domain (RBD) sequence SEQ ID NO:17, designed truncated S protein sequence SEQ ID NO:15, and designed full length S protein sequence SEQ ID NO:13. Designed coronavirus envelope (E), membrane (M), and nucleocapsid (N) protein sequences are also described, and their use as vaccines. Nucleic acid molecules encoding the polypeptides, vectors, fusion proteins, pharmaceutical compositions, cells, and their use as vaccines against viruses of the coronavirus family are also described.

The invention belongs to the technical field of pharmaceutical engineering, and particularly provides a preparation method of virus-like particles composed of truncated protein. The truncated protein is a norovirus target antigen truncated body, and the method comprises the following steps: (1) taking a host thallus for expressing a norovirus target antigen, and repeatedly freezing and thawing the host thallus; (2) suspending the frozen and thawed thalli in a buffer solution, and performing high-pressure homogenate crushing on the thalli until the crushing rate of the thalli is greater than or equal to 80% to obtain homogenate; carrying out crude purification on the homogenate to obtain a crude purified supernatant; and (3) standing the crude pure supernate under a certain condition, and then finely purifying to obtain the virus-like particles formed by the truncated protein. The method can be used for preparing sufficient and high-purity truncated protein at one time, and has important significance on quality research of broad-spectrum virus antigen vaccines.